Trial Profile
A Phase I, Open-Label, Single-Dose Study of MP-424 in Patients With Genotype 1b Hepatitis C
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 15 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Sep 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 07 Feb 2008 New trial record.